DSGN — Design Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1807120 ·
Last close
$12.12
Market Cap
$758.49M
52W High
$17.25
52W Low
$5.28
ADV30
718,087
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -22,177,000 | -20,165,000 | 215,129,000 | 12,907,000 | 13,271,000 |
| Mar 2026 | 0 | — | -19,706,000 | -17,636,000 | 230,442,000 | 12,770,000 | 12,388,000 |
| Dec 2025 | 0 | — | -18,169,000 | -15,997,000 | 226,203,000 | 16,856,000 | 13,700,000 |
| Sep 2025 | 0 | — | -19,311,000 | -16,997,000 | 211,770,000 | 15,088,000 | 12,050,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-55,083,000
Investing CF
$2,394,000
Financing CF
$45,893,000
CapEx
$-193,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,807,000
Inventory
—
Receivables
$1,786,000
ST Investments
$194,489,000
EBIT TTM
$-79,363,000
Pretax Income TTM
$-70,795,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -79,467,000 | -69,792,000 | 226,203,000 | 13,700,000 | 212,503,000 | -54,358,000 |
| Dec 2024 | 0 | -62,383,000 | -49,588,000 | 252,093,000 | 9,996,000 | 242,097,000 | -43,105,000 |
| Dec 2023 | 0 | -78,190,000 | -66,862,000 | 289,643,000 | 11,956,000 | 277,687,000 | -58,560,000 |
| Dec 2022 | 0 | -67,593,000 | -63,308,000 | 341,137,000 | 13,827,000 | 327,310,000 | -51,317,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.59
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $12.12 · call oi: 20,391 · put oi: 55Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $758.07M | $5.15 | — |
| IVEVF | Inventiva S.A. | $760.63M | $3.22 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $765.60M | $8.75 | — |
| SLNCF | Silence Therapeutics plc | $745.85M | $4.00 | — |
| WVE | Wave Life Sciences, Inc. | $744.84M | $3.78 | — |
News headlines (Yahoo Finance, 1h cache)
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
2026-05-18 11:00 · Yahoo
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
2026-05-18 14:02 · Yahoo
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
2026-05-17 20:00 · Yahoo
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
2026-05-11 16:00 · Yahoo
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
2026-04-28 20:01 · Yahoo
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
2026-04-29 23:00 · Yahoo
Design Therapeutics Q1 Earnings Call Highlights
2026-04-29 09:04 · Yahoo
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
2026-08-27 14:00 · Yahoo
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
2026-06-08 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.